The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials
Gita Thanarajasingam, Joleen M. Hubbard, Jeff A. Sloan, Axel Grothey
CARDIONCOLOGY.ORG ABSTRACT:
A consistent system for reporting adverse events (AEs) in cancer clinical trials is essential to ensure the safety and tolerability of chemotherapy. The advent of newer oral agents taken over long periods of time are significantly different from conventional cytotoxic intravenous therapies. Methods for reporting AEs have not evolved to reflect
the longitudinal toxicity profiles of the newer agents, and lack of time-related information has led to an incomplete and inaccurate depiction of AEs.
-
Cardiac Safety of Trastuzumab Emtansine in Breast Cancer
-
Could Erlotinib Led to Acute CVD Events in Lung Adenocarcinoma?
Unlike other targeted tyrosine kinase inhibitors, data on erlotinib do not indicate that is is associated with increased acute cardiovascular event (ACE) risk. Despite not being a cardiotoxic drug itself, preclinical studies suggest an aggregate effect of erlotinib on ACE, This article presents two non-small-cell lung cancer cases that developed ACE under erlotinib treatment.
© All rights reserved
image source: https://www.mdpi.com/2072-6651/11/9/507